Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 and AK117 in Advanced Malignant Tumors
NCT05229497Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in cancer, head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started May 2022; status: active, not recruiting.
02
Drugs
ligufalimab
03
Conditions
cancerhead and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05229497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229497.